EP1723148A2 - Derives de thieno-iminoacide en tant qu'inhibiteurs de metalloproteinases matricielles - Google Patents

Derives de thieno-iminoacide en tant qu'inhibiteurs de metalloproteinases matricielles

Info

Publication number
EP1723148A2
EP1723148A2 EP05700992A EP05700992A EP1723148A2 EP 1723148 A2 EP1723148 A2 EP 1723148A2 EP 05700992 A EP05700992 A EP 05700992A EP 05700992 A EP05700992 A EP 05700992A EP 1723148 A2 EP1723148 A2 EP 1723148A2
Authority
EP
European Patent Office
Prior art keywords
defined above
ring
het
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05700992A
Other languages
German (de)
English (en)
Inventor
Manfred Schudok
Hans Matter
Armin Hofmeister
Maxime Lampilas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of EP1723148A2 publication Critical patent/EP1723148A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the invention relates to new derivatives of thienyl-containing bi- and tricyclic imino acids, processes for their preparation and use thereof as medicaments.
  • Collagenases belong to the superfamily of
  • MMPs Metalloproteinases
  • P's matrix metal proteinases
  • the MMPs form a group of Zn-dependent enzymes which are involved in the biodegradation of the extracellular matrix (D. Yip et al. In Investigational New Drugs 17 (1999), 387-399 and Michaelides et al. In Current Pharmaceutical Design 5 ( 1999) 787-819).
  • MMP's are particularly capable of breaking down fibrillar and non-fibrillar collagen, as well as proteoglycans, both of which are important matrix components.
  • MMPs are involved in processes of wound healing, tumor invasion, metastasis migration as well as angiogenesis, multiple sclerosis and heart failure (Michaelides page 788; see above). In particular, they play an important role in the breakdown of the joint matrix in arthrosis and arthritis, be it osteoarthritis, osteoarthritis or rheumatoid arthritis.
  • MMP's The activity of MMP's is still essential for many of these processes, the formation of plaque play a role in the atherosclerotic how the infiltration inflarnmatorischer cells, smooth muscle cell migration and proliferation and angiogenesis (SJ George, Exp. Opin. Invest. Drugs (2000), 9 (5), 993-1007). Furthermore, the matrix degradation caused by MMPs can cause plaque instabilities or even ruptures, which can lead to the clinical symptoms of atherosclerosis, unstable angina pectoris, myocardial infarction or stroke (EJM Creemers et al, Circulation Res. 89, 201-210 (2001 )).
  • Neointima formation left ventricular remodeling, dysfunction of pump performance or infarct healing.
  • a detailed tissue analyzer also showed reduced collagen damage, improved extracellular matrix remodeling and improved structure and function of the heart muscle and vessels.
  • the matrix remodeling processes and MMP-regulated fibrosis in particular are regarded as important components in the progression of heart diseases (infarction) (Drugs 61, 1239-1252 (2001)).
  • MMP's cleave matrix proteins such as collagen, laminin, proteoglycans, elastin or gelatin as well as process (ie activate or deactivate) by cleaving a large number of other proteins and enzymes under physiological conditions, so that they play an important role in the entire organism, with particular importance in the connective tissue and bones.
  • process ie activate or deactivate
  • MMPs cause side effects.
  • the main side effects mentioned are musculoskeletal pain or anthralgia.
  • the prior art clearly states that it is expected that more selective inhibitors can reduce these side effects mentioned (Yip, page 387, see above).
  • a specificity in relation to MMP-1 should be particularly emphasized, since with the inhibition of MMP-1 these undesirable side effects obviously appear more frequently.
  • MMP inhibitors of the MMPs A frequent disadvantage of the known inhibitors of the MMPs is therefore the lack of specificity. Most MMP inhibitors inhibit many MMPs at the same time because the MMP's catalytic domain has a similar structure. Accordingly, the inhibitors have an undesirable effect on the enzymes, including those with vital function (Massova I, et al., The FASEB Journal (1998) 12, 1075-1095).
  • the derivatives used according to the invention are strong inhibitors of the matrix metalloproteinases MMP-2, MMP-3 MMP-8, MMP-9 and MMP-13, while only a weak inhibition of MMP-1 takes place.
  • the invention therefore relates to a compound of the formula
  • A represents - (Cn-C4) -alkylene
  • B, D and E are the same or different and independently of one another are - (Cn-C4) -alkylene or the radical -B1-B2-B3-, in which B1 is - (CH2, in which v is the integer zero, 1 or 2 means B3 is - (CH2) r ⁇ r, where m is the integer zero, 1 or 2, with the proviso that the sum of v and m is zero, 1 or 2, and B2 is 1) - C (O) - 2) - (C2-C4) alkenylene, 3) -S (O) 0 -, where o is the integer zero, 1 or 2, 4) -N (R6) -, where R6 is hydrogen atom , Methyl or ethyl means 5) -N (R6) -C (Y) -, wherein.
  • Y represents oxygen atom or sulfur atom and R6 is as defined above, 6) -C (Y) -N (R6) -, in which Y represents oxygen atom or sulfur atom and R6 is defined as above, 7) -N (R6) -S ⁇ 2-, wherein R6 is as defined above, 8) -S ⁇ 2-N (R6) -, where R6 is as defined above, 9) -N (R6) -S ⁇ 2-N (R6) -, wherein R6 is as defined above, 10) -N (R6) -C (Y) -N (R6) -, in which Y represents oxygen atom or sulfur atom and R6 is as defined above, 11) -OC (O) -N (R6) -, 12) -NH-C (O) -O-, 13) -O-, 14) -C (O) -O-, 15).
  • R12 a) hydrogen atom
  • b) - (Cj-C6) -alkyl in which alkyl is unsubstituted or mono-, di- or triple by halogen, - (C3-C6) -cycloalkyl, - (C2 - C6) alkynyl, - (Cß-Ci4) aryl or Het ring is substituted, c) - (C 6 -C 14 ) aryl, d) Het ring, e) -C (O) -O- R13, R13 wherein e) 1) - (Cj-C6) -alkyl, wherein alkyl is unsubstituted or mono- or disubstituted by - (C3-C6) -cycloalkyl, - (C 2 -C 6) alkynyl, - (CSS -C ⁇ aryl, or Het ring is substituted
  • the partial structure of the compound of the formula I is an unsaturated or partially saturated ring with 5 ring atoms, one of the ring atoms Z1,
  • Z2 or Z3 represents a sulfur atom and the other two ring atoms represent carbon atoms which are independently substituted by R2 or R3, where
  • R2 and R3 are identical or different and independently of one another for 1) hydrogen atom, 2) - (C ⁇ -CgJ-alkyl, in which alkyl is unsubstituted or mono- or disubstituted by - (C3-C6) -cycloalkyl, - (C ⁇ - CßJ-alkynyl, - (Cg-C ⁇ aryl or Het ring is substituted, 3) -C (O) -O-R8, in which R8 3) 1) hydrogen atom, 3) 2) - (-C-C6) -alkyl, in which alkyl is unsubstituted or mono- or disubstituted by - (C3-C ⁇ ) -cycloalky1, - (C2-C6) -alkynyl, - (Cß-C ⁇ J-aryl, or Het ring or substituted one to five times by fluorine, 3) 3) - (C-6-C
  • Y1 and Y2 are the same or different and independently of one another represent 1) hydrogen atom, 2) halogen, 3) -CN, 4) - (-C-C6) -alkyl, in which alkyl is unsubstituted or mono-, di- or triple by halogen, - (C3-C6) -cycloalkyl, - (C-2-C6) -alkynyl, - (Cß-Ci4) -aryl or Het-ring is substituted, 5) - (C 6 -C 14 ) -aryl, 6) Het-Ring, 7) -C (O) -O-R10, in which R10 is as defined above, 8) -C (S) -O-R10, in which R10 is as defined above, 9) -C (O) -NH-R11, wherein R11 is as defined above, 10) -C (S) -NH-R11, wherein R11 is as defined above, 11)
  • q and r independently of one another represent the integer 2, 3 or 4 and the radicals - (CH2) q - or - (CH2) r are unsubstituted or mono- or disubstituted by - (Ci-CßJ-alkyl, - (C2 -Cfi) alkynyl, - (C3-C6) -cycloalkyl, - (C6-C ⁇
  • the invention further relates to the compound of the formula I, where A is - (Cn-C4) -alkylene,
  • B, D and E are the same or different and independently of one another are - (Co-C4) alkylene or the radical -B1-B2-B3-, in which B1 is - (CH2) V -, in which v is the integer zero , 1 or 2 means B3 is - (CH2) -, where m is the integer zero, 1 or 2, with the proviso that the sum of v and m is zero, 1 or 2, and B2 is 1) -C (O) - 2) - (C2-C-4) alkenylene, 3) -S (O) 0 -, where o is the integer zero, 1 or 2, 4) -N (R6) -, where R6 is hydrogen, methyl or Ethyl means 5) -N (R6) -C (Y) -, in which Y represents oxygen atom or sulfur atom and R6 is as defined above, 6) -C (Y) -N (R6) -, in which Y represents oxygen atom or sulfur atom and R
  • G for 1) hydrogen atom, 2) halogen, 3) O, 4) - (C-
  • R11 a) - (C-
  • X stands for -OH or -NH-OH
  • n stands for the integer zero, 1 or 2
  • R2 and R3 are identical or different and independently of one another for 1) hydrogen atom, 2) - (Cj-CgJ-alkyl, in which alkyl is unsubstituted or mono- or disubstituted by - (C3-C6) -cycloalkyl, - (C2-C6) - Alkynyl, - (C6-Ci4) -aryl or Het ring is substituted, whereby aryl and Het ring are as defined above, 3) -C (O) -O-R8, in which R8 3) 1) hydrogen atom, 3) 2) - (Ci -CßJ-alkyl, in which alkyl is unsubstituted or mono- or doubly by - (C3-C6) -cycloalkyl, - ⁇ - CßJ-alkynyl, - (Cß-C ⁇ aryl, or Het ring, wherein Aryl and Het ring are as defined above, or
  • Y1 and Y2 are the same or different and stand independently of one another for 1) hydrogen atom, 2) halogen, 3) -CN, 4) - (Ci-CgJ-alkyl, in which alkyl is unsubstituted or mono-, di- or triple by halogen , - (C3-C6) -cycloalkyl, - (C2-C6) -alkynyl, - (CQ-C-
  • R12 is as defined above and R16 for 1) hydrogen atom
  • R12 is as defined above and R16 for 1) hydrogen atom
  • R16 for 1) hydrogen atom
  • R12 is as defined above and R16 for 1) hydrogen atom
  • R16 for 1) hydrogen atom
  • - (-C-C6) -alkyl in which alkyl is unsubstituted or mono- or disubstituted by - (C3-C6 ) -Cycloalkyl, - (C 2 -Cfi) alkynyl, - (C6-Ci4) -aryl or Het ring, where aryl and Het ring are as defined above, 3) -C (O) - O-R8, wherein R8 is as defined above, 4) -O-R8, wherein R8 is as defined above, or 5) - (C3-C6) -cycloalkyl, or
  • q and r independently of one another represent the integer 2, 3 or 4 and the radicals - ( C 2) q- or - (CH2) r are unsubstituted or mono- or disubstituted by - (Cj-CßJ-alkyl, - ( C2-C6) alkynyl, - (C3-C6) -cycloalkyl, - (Cfi-C-
  • the invention further relates to the compound of the formula I, where A is - (Cn-C4) -alkylene,
  • B, D and E are the same or different and independently of one another are - (Co- C2) alkylene or the radical -B1-B2-B3-, where B1 is - (CH2) -, where v is the integer zero, 1 or 2 means B3 is - (CH2) m -, where m is the integer zero, 1 or 2, with the proviso that the sum of v and m is zero, 1 or 2, and B2 is 1) ethenylene, 2) ethynylene, 3) -C (O) - 4) -N (R6) -C (O) -, where R6 is hydrogen, methyl or ethyl, 5) -C (O) -N (R6 ) -, where R6 is as defined above, 6) -O- or 7) -S-, ringl, ririg2 or ringS are identical or different and independently of one another represent 1) covalent bond, 2) is phenyl or naphthyl and are
  • Het ring in which the Het ring is a radical from the series dihydrofuranyl, furanyl, pyridyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl or thiophenyl and are unsubstituted or independently substituted once or twice by G
  • ring4 represents 1) phenyl or naphthyl and is unsubstituted or independently of one another or is substituted twice by G
  • Het ring in which the Het ring is a radical from the series benzofuranyl, dihydrofuranyl, dibenzofuranyl, dibenzothiophenyl, furanyl, morpholinyl , Piperazinyl, piperidyl, pyridinyl, pyrimidinyl, pyridothiophenyl, pyrrolyl, pyrrolidinyl, thiazolyl or thiophenyl means and unsubstit
  • G represents 1) hydrogen atom, 2) Br, Cl or F, 3) - (C-] -C4) -alkyl, in which alkyl is unsubstituted or mono- or disubstituted by F , Phenyl, -C3-cycloalkyl or Het ring, where Het ring is as defined above for ring4, 4) phenyl, 5) Het ring, where Het ring is as defined for ring4 above,
  • Another object of the invention is the compound of formula I, wherein
  • A represents a covalent bond or -CH2-CH2-
  • B, D and E are the same or different and independently of one another are - (CQ-C-2) alkylene or the radical -B1-B2-B3-, in which B1 is - (CH2) V -, in which v is the whole Number zero, 1 or 2,
  • B3 stands for - (CH2) m-, where m is the integer zero, 1 or 2, with the proviso that the sum of v and m is zero, 1 or 2, and B2 for 1) -C (O) - 2) ethynylene, 3) -S-, 4) -N (R6) -C (O) -, where R6 is hydrogen atom, 5) -C (O) -N ( R6) -, in which R6 represents hydrogen atom, or 6) -O- ringl, ring2 or ring3 are identical or different and independently of one another represent 1) covalent bond, 2) represents phenyl and is unsub
  • G represents 1) hydrogen atom, 2) Br, Cl or F, 3) - (C- ⁇ -C4) -alkyl, wherein alkyl is unsubstituted or mono-, di- or triple is substituted by Br, Cl, F, -C3 cycloalkyl, phenyl or Het ring, where Het ring is as defined above for ring4, 4) phenyl, 5) Het ring, where Het ring is defined as above for ring4 is 6) -C (O) -O-R10, in which R10 a) - (C-
  • X represents -NH-OH
  • n stands for the integer 1
  • R2 and R3 are the same and represent hydrogen or R2 and R3 together with the carbon atoms to which they are attached form a phenyl ring, in which the ring is unsubstituted or mono- or disubstituted by G, Y1 and Y2 are the same or different and independently of one another represent a) hydrogen atom, b) -O-R12, where R12 is as defined above, c) -OC (O) -R10, where R10 is as defined above, or d) -N (R15) -R12, where R15 is as defined above, or Y1 and Y2 together form O, or Y1 and Y2 together with the carbon atom to which they are each bonded form a partial structure of the compound of the formula I.
  • Another object of the invention is the connection
  • (Ci-CgJ-alkyl) is understood to mean hydrocarbon radicals whose carbon chain is straight-chain or branched and contains 1 to 6 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary-butyl, pentyl , Iso-pentyl, neopentyl, hexyl, 2,3-dimethylbutane or neohexyl.
  • - (Co-C4) alkylene is understood to mean hydrocarbon radicals whose carbon chain is straight-chain or branched and contains 1 to 4 carbon atoms, for example methylene , Ethylene, propylene, iso-propylene, iso-butylene, butylene or tertiary butylene.
  • -Crj-alkylene is a covalent bond.
  • n denotes the integer zero, 1 or 2
  • n denotes the integer zero
  • n is understood to mean a covalent bond for n equal to zero, n equal to 1 the residue methylene and n equal to 2 the residue ethylene.
  • the term - (C2-C4) -alkenylene, “are understood hydrocarbon radicals, the carbon chain of which is straight-chain or branched and contains 2 to 4 carbon atoms and, depending on the chain length, have 1 or 2 double bonds, for example ethenylene, propenylene, iso-propenylene, isobutylene or butenylene; the substituents on the double bond can, if the principal possibility exists, be arranged in E or Z positions.
  • - (C2-C6) -alkynylene is understood to mean hydrocarbon radicals whose carbon chain is straight-chain or branched and contains 2 to 6 carbon atoms and, depending on the chain length, has 1 or 2 triple bonds, for example ethynylene, propinylene, isopropynylene, Isobutylinylene, butyynylene, pentinylene or isomers of pentinylene or hexinylene or isomers of hexinylene.
  • (C3-C7) cycloalkyl is understood to mean radicals such as compounds which are derived from 3- to 7-membered monocycles such as cyclopropyl, cyclobutyl , Cyclopentyl, cyclohexyl or cycloseptyl.
  • 4) -aryl is understood to mean aromatic hydrocarbon radicals having 6 to 14 carbon atoms in the ring.
  • aryl radicals are, for example, phenyl, naphthyl, for example 1-naphthyl, 2-naphthyl, anthryl or fluorenyl.
  • Het ring is understood to mean ring systems with 4 to 15 carbon atoms which are present in one, two or three interconnected ring systems and which are one, two, three or four identical or contain various heteroatoms from the series consisting of oxygen, nitrogen or sulfur.
  • Examples of these ring systems are the residues acridinyl, azepinyl, azetidinyl, aziridinyl, benzimidazalinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, carbobothotholazolyl, carbobothothiazolyl, benzisotholazolyl, carbobothothiazolyl, carbobothothiazolyl, carbobothothiazolyl, carbobothothiazolyl, carbobothothiazolyl, carbobothothiazolyl, carbobothyazolyl, carbobothylazolyl, carbobenzothylolol, carbobenzylsolazolyl, carbobenzylsolazole, carbobenzyls
  • Preferred Het rings are the residues benzofuranyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, 1, 3-benzodioxolyl, quinazolinyl, quinolinyl, quinoxalinyl, chromanyl, cinnolinyl, furanyl; such as 2-furanyl and 3-furanyl; Imidazolyl, indolyl, indazolyl, isoquinolinyl, isochromanyl, isoindolyl, isothiazolyl, Isoxazolyl, oxazolyl, phthalazinyl, pteridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyridyl; such as 2-pyridyl
  • the invention further relates to a process for the preparation of the compound of formula I and / or a stereoisomeric form of the compound of formula I and / or a physiologically tolerable salt of the compound of formula I, which is characterized in that a) a compound of the generic Formula IV,
  • Re represents a hydrogen atom or an ester protecting group and n Yi, Y 2 , Zi, Z 2 , Z 3> R2 and R3 are as defined for the compound of formula I, with a compound of formula V,
  • Pictet-Spengler-like ones can also be found here Cyclizations of 2- (3-thienyl) ethylamines with corresponding glyoxylates or a combination of alkylation of suitable precursors and Friedel-Crafts acylation are used.
  • substituents can also be present on the ethylamine side chain, so that the corresponding substituted tetrahydrothienopyridines are then obtained.
  • Substituted or unsubstituted benzothienylethylamines can also be used in cyclization reactions.
  • the 4-keto precursors are preferably used to prepare the 4-hydroxy compounds according to the invention described in more detail in the examples. The synthesis of the nitrogen and the
  • Carboxylic acid-protected keto starting compounds are described in detail analogously, for example, in WO 2002100860. 4,5,6,7-Tetrahydro-thieno [3,4-c] pyridines are described, for example, in US5,294,621. described. Analog syntheses with corresponding starting products lead to the 4,5,6,7-tetrahydro-thieno [3,4-c] pyridine-4-carboxylic acids.
  • starting products are preferred which are substituted by R2 or R3 on the thiophene, for example thienyl-3-alkylamines, which can be used in the cyclization reaction mentioned and lead to the corresponding regiochemistry of the newly formed bicyclic system.
  • the starting products for the preparation of such thienylalkylamines are, for example, 2-substituted thiophene-3-aldehydes which are prepared by known processes and are further reacted to give the alkylamines.
  • ester protective groups are, for example, methyl, ethyl, isopropyl Butyl or benzyl.
  • Type IV compounds in an N-protected state.
  • compounds protected in this way can be purified better than the free imino acids.
  • U. can also be used better for the preparation of enantiomerically or diastereomerically pure compounds.
  • the groups described in "Protective Groups in Organic Synthesis", TH Greene, PGM Wuts, Wiley-Interscience, 1999, can be used as protecting groups.
  • Preferred amino or imino protecting groups are, for example, Z, Boc, Fmoc, aloe, acetyl , Trifluoroacetyl, benzoyl, benzyl and the like.
  • the starting materials and reagents used can either be prepared by known processes or are commercially available.
  • the reactions are carried out, for example, as shown in WO 97/18194.
  • the reaction according to process step a) takes place in the presence of a base such as KOH, NaOH, LiOH, N-methylmorpholine (NMM), N-ethylmorpholine (NEM), triethylamine (TEA), diisopropylethylamine (DIPEA), pyridine, collidine, imidazole or Sodium carbonate, in solvents such as tetrahydrofuran (THF), dimethylformamide (DMF), dimethylacetamide, dioxane, acetonitrile, toluene, chloroform or methylene chloride, or in the presence of water.
  • a base such as KOH, NaOH, LiOH, N-methylmorpholine (NMM), N-ethylmorpholine (NEM), triethylamine (TEA), diisopropylethylamine (DIPEA), pyridine, collidine
  • Modifications in the side chain F means that, for example, a nitro group is hydrogenated with the metal catalyst Pd / C or reacted with SnCl2 or Zn under standard conditions and the amino group obtained can then be further modified, for example by reaction with carboxylic acid chlorides, sulfonic acid chlorides, chloroformic acid esters, isocyanates, Isothiocyanates or other reactive or activatable reagents to arrive at the precursors of the compounds of formula I according to the invention. In this case it is often favorable that Re in compound VI is an ester, since side reactions are to be expected in the case of the unprotected carboxylic acid.
  • the compound of formula I if it occurs as a mixture of diastereomers or enantiomers or occurs in the chosen synthesis as their mixtures, is separated into the pure stereoisomers, either by chromatography on an optionally chiral support material or, if the racemic Compound of formula I is capable of salt formation, by fractional crystallization of the diastereomeric salts formed with an optically active base or acid as auxiliary.
  • Modified silica gel supports so-called Pirkle phases
  • the optically active, generally commercially available base such as (-) - nicotine, (+) - and (-) - phenylethylamine, quinine bases, L-lysine or L- and D-arginine are used to dissolve the differently soluble ones diastereomeric salts formed, the less soluble component isolated as a solid, the more soluble diastereomer separated from the mother liquor and the pure enantiomers obtained from the diastereomeric salts thus obtained.
  • racemic compounds of the formula I which contain a basic group such as an amino group
  • optically active acids such as (+) - camphor-10-sulfonic acid, D- and L-tartaric acid, D- and L- Convert lactic acid and (+) and (-) - mandelic acid into the pure enantiomers.
  • the chirality of the amino acid or alcohol residue introduced in enantiomerically pure form can then be used to separate the isomers by separating the diastereomers now present by crystallization or chromatography on suitable stationary phases and then cleaving off the chiral part of the molecule which is carried along using suitable methods.
  • chiral glyoxylic acid esters such as menthol esters
  • Pictet-Spengler cyclizations with e.g. B. thienylethylamines can be used.
  • 2-3-Dihydrothiophene derivatives can be prepared from the corresponding thiophenes.
  • a large number of processes are known to the person skilled in the art. More recent methods are described, for example, in Organometallics 22 (23), 4803 (2003) or in J. of Molecular Catalysis A: Chemical, 189 (2), 211-17 (2002). These processes are successfully used when R2 and R3 together, in the case of Z1 or Z2 equal to sulfur, form an aryl system. In this way a hexahydropyridine system is obtained.
  • An exemplary compound is 1, 2,3,4,4a, 9b-hexahydro-benzo [4,5] thieno [3,2-c] pyridine-1-carboxylic acid.
  • Acidic or basic products of the compound of formula I can be in the form of their salts or in free form.
  • the preparation of physiologically compatible salts from compounds of the formula I capable of salt formation, including their stereoisomeric forms, in process step d) is carried out in a manner known per se.
  • the compounds of the formula I form, with basic reagents such as hydroxides, carbonates, hydrogen carbonates, alcoholates and ammonia or organic bases, for example trimethylamine or triethylamine, ethanolamine, diethanolamine or triethanolamine, trometamol or else basic amino acids, for example lysine, ornithine or arginine, stable alkali -, Alkaline earth metal or optionally substituted ammonium salts.
  • basic reagents such as hydroxides, carbonates, hydrogen carbonates, alcoholates and ammonia or organic bases, for example trimethylamine or triethylamine, ethanolamine, diethanolamine or triethanolamine, trometamol or else basic amino acids, for example lysine, ornithine or arginine, stable alkali -, Alkaline earth metal
  • Both inorganic and organic acids such as hydrogen chloride, hydrogen bromide, sulfur, hemisulfur, phosphorus, methanesulfone, benzenesulfone, p-toluenesulfone, 4-bromobenzene-sulfone,
  • the invention also relates to pharmaceuticals, characterized by an effective content of at least one compound of the formula I and / or a physiologically tolerable salt of the compound of the formula I and / or an optionally stereoisomeric form of the compound of the formula I, together with a pharmaceutically suitable and physiological compatible carrier, additive and / or other active substances and auxiliaries.
  • the compounds according to the invention are suitable for the selective prophylaxis and therapy of all such diseases, the course of which involves an increased activity of the metalloproteinases.
  • diseases include degenerative joint diseases such as osteoarthrosis, spondylosis, cartilage loss after joint trauma or long immobilization after meniscus or patella injuries or Torn ligaments.
  • connective tissue diseases such as collagenosis, periodontal diseases, wound healing disorders and chronic musculoskeletal disorders such as inflammatory, immunological or metabolic acute and chronic arthritis, arthropathy, myalgia and disorders of bone metabolism.
  • the compounds of the formula I are also suitable for the treatment of ulceration, atherosclerosis and stenoses.
  • the compounds of the formula I are also suitable for the treatment of inflammation, cancer, tumor metastasis, cachexia, anorexia, heart failure and septic shock.
  • the compounds are also suitable for the prophylaxis of myocardial and cerebral infarcts.
  • the medicaments according to the invention can be administered by oral, inhalative, rectal or transdermal application or by subcutaneous, intra-articular, intraperitoneal or intravenous injection. Oral application is preferred.
  • the invention also relates to a method for producing a medicament, which is characterized in that at least one compound of the formula I is brought into a suitable dosage form with a pharmaceutically suitable and physiologically tolerable carrier and, if appropriate, other suitable active ingredients, additives or auxiliaries.
  • Suitable solid or galenical forms of preparation are, for example, granules, powders, dragees, tablets, (micro) capsules, suppositories, syrups, juices, suspensions, emulsions, drops or injectable solutions as well as preparations with protracted active ingredient release, in the preparation of which conventional auxiliaries such as carriers, Explosives, binders, coating agents, swelling agents, lubricants or lubricants, flavorings, sweeteners and solubilizers are used.
  • conventional auxiliaries such as carriers, Explosives, binders, coating agents, swelling agents, lubricants or lubricants, flavorings, sweeteners and solubilizers are used.
  • Magnesium carbonate, titanium dioxide, lactose, mannitol and other sugar, talc, milk protein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils such as cod liver oil are frequently used as auxiliary substances.
  • the pharmaceutical preparations are preferably produced and administered in dosage units, each unit containing as active ingredient a certain dose of the compound of the formula I according to the invention.
  • this dose can be up to about 1000 mg, but preferably about 50 to 300 mg, and for injection solutions in ampoule form up to about 300 mg, but preferably about 10 to 100 mg.
  • daily doses for the treatment of an adult patient weighing approximately 70 kg, daily doses of approximately 2 mg to 1000 mg of active ingredient, preferably approximately 50 mg to 500 mg, are indicated, depending on the effectiveness of the compound according to formula I. In certain circumstances. however, higher or lower daily doses may also be appropriate.
  • the daily dose can be administered either as a single dose in the form of a single dose unit or else several smaller dose units or as a multiple dose divided at certain intervals.
  • End products are usually determined by mass spectroscopic methods (FAB-, ESI-MS) and 1 H-NMR (400 MHz, in DMSO-D6), the main peak or the two main peaks are given in each case.
  • Temperatures in degrees Celsius, RT means room temperature (21 ° C to 24 ° C). Abbreviations used are either explained or correspond to the usual conventions.
  • the carboxylic acid was dissolved in 0.5-2 molar NaOH, possibly with the addition of 10-50% tetrahydrofuran (THF) or DMF. Acid chloride (1-1.2 equivalents, preferably 1.1) was dissolved in THF (concentration 0.05 to 1 M) and slowly added dropwise. 2 N NaOH was automatically added at RT to the autotitrator to keep the pH constant. Set pH: 8 to 12, preferably 9 to 11. After
  • the organic co-solvent was removed on a rotary evaporator, the aqueous solution or suspension was mixed with ethyl acetate and acidified with 1 N HCl. After the organic phase had been separated off and the aqueous phase had been extracted again with ethyl acetate, the organic phases were combined, dried over sodium sulfate and the solvent was then removed under reduced pressure. The crude product was either directly reacted further or purified by chromatography.
  • General instruction 3 sulfonamide from sulfonic acid chloride and carboxylic acid. This regulation is particularly suitable for the implementation of Biphenylethylsulfonyl chloride or similar, more hydrolysable labile sulfonyl chlorides with iminocarboxylic acids.
  • the sulfonated carboxylic acid was dissolved in 10 ml of DMF and at 0 ° C with 1.1
  • the sulfonated carboxylic acid was placed in dry chloroform (ethanol-free) (about 5 ml for 0.5 mmol) and 3 equivalents of oxalyl chloride were added at RT. The mixture was then heated to 45 ° C. for about 30 minutes. To control the Chloride formation was a small sample taken from the reaction flask and a little benzylamine in THF was added. The complete implementation could be recognized by the quantitative formation of benzylamide, the carboxylic acid was no longer detectable (control HPLC-MS). You may need to heat for a long time or heat under reflux conditions. The solvent was then distilled off under reduced pressure, the residue was taken up several times in dry toluene and evaporated again.
  • control HPLC-MS control HPLC-MS
  • Step 1 4-Hydroxy-3,4-dihydro-1 H-benzo [4,5] thieno [3,2-c] pyridine-1,2-dicarboxylic acid 2-tert-butyl ester 1-ethyl ester
  • Step 2 4-Hydroxy-3,4-dihydro-1H-benzo [4,5] thieno [3,2-c] pyridine-1-carboxylic acid
  • the residue obtained in step 1 (0.96 g, 2.6 mmol) was treated with 30 ml of TFA / methylene chloride 1: 2 for 1 hour at RT to remove the Boc protective group, then the solvent was removed under reduced pressure and the Ester cleavage treated directly with sodium hydroxide solution (0.7 ml, 2 molar) in 3 ml THF. The mixture was stirred overnight and, after checking the reaction, evaporated by HPLC-MS. The residue obtained was implemented further.
  • Step 3 2- (4'-chlorobiphenyl-4-sulfonyl) -4-hydroxy-1, 2,3,4-tetrahydrobenzo [4,5] thieno [3,2-c] pyridine-1-carboxylic acid
  • the product of the previous stage (342 mg, 1.33 mmol) was taken up in 10 ml of THF and after addition of 4 ml of sodium hydroxide solution (1 molar) or 4-chlorobiphenyl-4'-sulfonyl chloride (420 mg, 1.46 mmol) stirred overnight. The solvent was then removed under reduced pressure, the residue was taken up in ethyl acetate and extracted with dilute HCl or saturated NaCl solution. After drying over sodium sulfate, the solvent was removed under reduced pressure and the product obtained was reacted further.
  • Stage 4 - final product 2- (4'-chloro-biphenyl-4-sulfonyl) -4-hydroxy-1, 2,3,4-tetrahydro-benz [4,5] thieno [3,2- c] pyridine- 1-carboxylic acid hydroxyamide
  • Pharmacological examples Determination of the enzymatic activity of the catalytic domain of human collagenase-1 (MMP-1). This protein is obtained as an inactive pro-enzyme from Biocol, Potsdam (catalog no. MMP1). Activation of the proenzyme: 2 parts by volume of proenzyme are incubated with 1 part by volume of APMA solution at 37 ° C. for 1 hour.
  • the APMA solution is prepared from a 10 mmol / L p-aminophenyl-mercuric acetate solution in 0.1 mmol / L NaOH by dilution with 3 volumes of Tris / HCl buffer pH7.5 (see below).
  • the pH is adjusted between 7.0 and 7.5 by adding 1 mmol / L HCl. After activation of the enzyme, it is diluted with the Tris / HCl buffer to a concentration of 2.5 ⁇ g / mL.
  • 10 ⁇ L of enzyme solution are incubated with 10 ⁇ L of a 3% (v / v) buffered dimethyl sulfoxide solution (reaction 1) for 15 minutes.
  • 10 ⁇ L of enzyme solution are incubated with 10 ⁇ L of a 3% (v / v) buffered dimethyl sulfoxide solution which contains the enzyme inhibitor (reaction 2).
  • reaction 1 after adding 10 ⁇ L of a 3% (v / v) aqueous dimethyl sulfoxide solution containing 0.3 mmol / L of the substrate, the enzyme reaction is monitored by fluorescence spectroscopy (328 nm (extinction) / 393 nm (emission)). The enzyme activity is represented as the increase in extinction / minute.
  • Inhibitor concentration is determined graphically by plotting the percent inhibitions at different inhibitor concentrations.
  • the enzyme solution contains 2.5 ⁇ g / mL of the enzyme domain.
  • the substrate solution contains 0.3 mmol / L of the fluorogenic substrate (7-methoxycoumarin-4-yl) acetyl-Pro-Leu-Gly-Leu-3- (2 ', 4 , -dinitrophenyl) -L-2,3-diaminopropionyl -Ala-Arg-NH2 (Bachern, Heidelberg, Germany).
  • MMP-3 Human stromelysin
  • MMP-3 The two enzymes - streamelysin (MMP-3) and neutrophil collagenase (MMP-8)
  • the enzyme activity is represented as the increase in extinction / minute.
  • the IC o values listed in Table 2 were determined as the inhibitor concentration which in each case led to a 50% inhibition of the enzyme.
  • the MMP-3 enzyme solution contained 2.3 ⁇ g / ml, the MMP-8 enzyme solution 0.6 ⁇ g / ml one of those according to Ye et al. enzyme domains shown.
  • the substrate solution contained
  • This protein was obtained as an inactive pro-enzyme from INVITEK, Berlin (catalog No. 30 100 803). Activation of the proenzyme:
  • Tris / HCl buffer pH7.5 (see below) were prepared. The pH was adjusted between 7.0 and 7.5 by adding 1 mmol / L HCl. After activation of the enzyme, it was diluted with the Tris / HCl buffer to a concentration of 1.67 ⁇ g / mL.
  • reaction 1 To measure the enzyme activity, 10 ⁇ L of enzyme solution were incubated with 10 ⁇ L of a 3% (v / v) buffered dimethyl sulfoxide solution (reaction 1) for 15 minutes. To measure the enzyme inhibitor activity, 10 ⁇ L of enzyme solution were incubated with 10 ⁇ L of a 3% (v / v) buffered dimethyl sulfoxide solution which contained the enzyme inhibitor (reaction 2).
  • the IC50 which is the inhibitor concentration required for 50% inhibition of enzyme activity, was determined graphically by plotting the percent inhibitions at various inhibitor concentrations.
  • the enzyme solution contained 1.67 ⁇ g / mL of the enzyme domain.
  • the substrate solution contained 0.075 mmol / L of the fluorogenic substrate (7-methoxycoumarin-4-yl) acetyl-Pro-Leu-Gly-Leu-3- (2 ', 4'-dinitrophenyl) -L-2,3-diaminopropionyl-Ala -Arg-NH 2 (Bachern, Heidelberg, Germany).
  • This protein was obtained as an inactive pro-enzyme from INVITEK, Berlin (catalog no. 30 100 602). Activation of the proenzyme:
  • APMA solution 2 parts by volume of proenzyme were incubated with 1 part by volume of APMA solution at 37 ° C. for 0.5 hours.
  • the APMA solution was diluted with a 10 mmol / L p-aminophenyl-mercuric acetate solution in 0.1 mmol / L NaOH
  • Tris / HCl buffer pH7.5 3 volumes were prepared. The pH was adjusted between 7.0 and 7.5 by adding 1 mmol / L HCl. After activation of the enzyme, it was diluted with the Tris / HCl buffer to a concentration of 0.83 ⁇ g / mL.
  • 10 ⁇ L of enzyme solution were incubated with 10 ⁇ L of a 3% (v / v) buffered dimethyl sulfoxide solution (reaction 1) for 15 minutes.
  • reaction 2 3 volumes of Tris / HCl buffer pH7.5 (see below) were prepared. The pH was adjusted between 7.0 and 7.5 by adding 1 mmol / L HCl. After activation of the enzyme, it was diluted with the Tris / HCl buffer to a concentration of 0.83 ⁇ g / mL.
  • 10 ⁇ L of enzyme solution were incubated with 10 ⁇ L of a 3% (v / v) buffered dimethyl sulfoxide solution (reaction 1) for
  • reaction 1 10 ⁇ L of a 3% (v / v) aqueous dimethyl sulfoxide solution containing 0.3 mmol / L des Contained substrate, the enzyme reaction followed by fluorescence spectroscopy (328 nm (extinction) / 393 nm (emission)).
  • Enzyme activity was shown as an increase in absorbance / minute.
  • the inhibitory effect was calculated as a percentage inhibition according to the following formula:
  • the IC50 this is the inhibitor concentration required for 50% inhibition of the
  • Enzyme activity required was determined graphically by plotting the percent inhibitions at various inhibitor concentrations.
  • the enzyme solution contained 0.83 ⁇ g / mL of the enzyme domain.
  • the substrate solution contained 0.3 mmol / L of the fluorogenic substrate (7-methoxycoumarin-4-yl) acetyl-Pro-Leu-Gly-Leu-3- (2 ', 4 , -dinitrophenyl) -L-2,3-diaminopropionyl -Ala-Arg-NH2 (Bachem, Heidelberg, Germany).
  • the pH was adjusted between 7.0 and 7.5 by adding 1 mmol / L HCl. After activation of the enzyme, it was diluted with the Tris / HCl buffer to a concentration of 4.2 mU / mL.
  • 10 ⁇ L of enzyme solution were incubated with 10 ⁇ L of a 3% (v / v) buffered dimethyl sulfoxide solution (reaction 1) for 15 minutes.
  • 10 ⁇ L of enzyme solution were used Incubate 10 ⁇ L of a 3% (v / v) buffered dimethyl sulfoxide solution containing the enzyme inhibitor (reaction 2).
  • Enzyme activity was represented as an increase in absorbance / minute.
  • the IC50 this is the inhibitor concentration required for 50% inhibition of the
  • Enzyme activity required was determined graphically by plotting the percent inhibitions at various inhibitor concentrations.
  • the enzyme solution contained 4.2 mU / mL of the enzyme domain.
  • the substrate solution contained 0.15 mmol / L of the fluorogenic substrate (7-methoxycoumarin-4-yl) acetyl-Pro-Leu-Gly-Leu-3- (2, 4'-dinitrophenyl) -L-2,3-diaminopropionyl -Ala-Arg-NH 2 (Bachem, Heidelberg, Germany).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne des composés de formule (I) qui conviennent à la préparation de produits pharmaceutiques destinés à la prévention et au traitement de maladies dont l'évolution est liée à une activité amplifiée de métalloprotéinases matricielles. Parmi ces maladies figurent les maladies de dégénérescence des articulations telles que les ostéoporoses, les spondyloses, la dégradation des cartilages après un traumatisme articulaire ou une immobilisation à long terme d'une articulation suite à des lésions du ménisque ou de la rotule ou des déchirures ligamentaires, ou une affection des tissus conjonctifs telle que les collagénoses, les maladies périodontales, les troubles de la cicatrisation, ou une maladie chronique de l'appareil moteur telle que les arthrites aiguës ou chroniques inflammatoires, d'origine immunologique ou métabolique, les arthropathies, les myalgies ou des troubles du métabolisme osseux, ou une ulcération, une athérosclérose ou une sténose. Les composés de formule (I) conviennent également au traitement d'inflammations, de maladies cancéreuses, de la formation de métastases tumorales, de la cachexie, de l'anorexie, de l'insuffisance cardiaque et du choc septique, et à la prévention de l'infarctus du myocarde et de l'accident vasculaire cérébral.
EP05700992A 2004-01-31 2005-01-18 Derives de thieno-iminoacide en tant qu'inhibiteurs de metalloproteinases matricielles Withdrawn EP1723148A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004004974A DE102004004974A1 (de) 2004-01-31 2004-01-31 Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
PCT/EP2005/000417 WO2005073236A2 (fr) 2004-01-31 2005-01-18 Derives de thieno-iminoacide en tant qu'inhibiteurs de metalloproteinases matricielles

Publications (1)

Publication Number Publication Date
EP1723148A2 true EP1723148A2 (fr) 2006-11-22

Family

ID=34801393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05700992A Withdrawn EP1723148A2 (fr) 2004-01-31 2005-01-18 Derives de thieno-iminoacide en tant qu'inhibiteurs de metalloproteinases matricielles

Country Status (5)

Country Link
US (1) US7399770B2 (fr)
EP (1) EP1723148A2 (fr)
JP (1) JP4733648B2 (fr)
DE (1) DE102004004974A1 (fr)
WO (1) WO2005073236A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361075A1 (de) * 2003-12-22 2005-07-28 Pac Tech - Packaging Technologies Gmbh Verfahren und Vorichtung zur Trocknung von Schaltungssubstraten
DE102004053982B4 (de) * 2004-11-09 2011-07-21 Koop, Daniel, 25337 Verwendung von Reibhölzern und Verfahren zum Räuchern von Nahrungsmittelprodukten
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
AU2010325925B2 (en) 2009-12-04 2016-02-25 Pgi Drug Discovery Llc. Multicyclic compounds and methods of use thereof
MA45857A (fr) 2016-07-29 2021-05-19 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
JP2019523279A (ja) 2016-07-29 2019-08-22 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 化合物および組成物ならびにそれらの使用
AU2018220509B2 (en) 2017-02-16 2022-04-28 Sunovion Pharmaceuticials Inc. Methods of treating schizophrenia
CA3070993A1 (fr) 2017-08-02 2019-02-07 Sunovion Pharmaceuticals Inc. Composes d'isochromane et leurs utilisations
KR20200122345A (ko) 2018-02-16 2020-10-27 선오비온 파마슈티컬스 인코포레이티드 염, 결정 형태 및 이들의 제조 방법
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
CA3180115A1 (fr) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7 h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine pour le traitement de troubles neurologiques et psychiatriques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006410A1 (fr) * 1997-08-04 1999-02-11 Amgen Inc. Inhibiteurs de metalloproteases heterocycliques hybrides et substitues par de l'acide hydroxamique

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294621A (en) 1992-10-07 1994-03-15 Ortho Pharmaceutical Corporation Thieno tetrahydropyridines useful as class III antiarrhythmic agents
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
WO1994028889A1 (fr) 1993-06-08 1994-12-22 Neogenix, Inc. Composes synthetiques et naturels purifies pour le traitement de l'osteo-arthrite
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
ES2170884T5 (es) * 1995-11-13 2007-04-01 Sanofi-Aventis Deutschland Gmbh Acidos alfa-iminohidroxamicos y carboxilicos n-sustituidos, ciclicos y heterociclicos.
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK0927183T3 (da) * 1996-08-28 2004-11-29 Procter & Gamble Spirocykliske metalloprotease-inhibitorer
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
WO2003016248A2 (fr) * 2001-08-17 2003-02-27 Bristol-Myers Squibb Company Patent Department Hydroxamates bicycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou enzyme de conversion du tnf-$g(a) (tace)
AU2003227648A1 (en) * 2002-04-22 2003-11-03 Ibfb Gmbh Substituted pyrimidine-2,4(1h,3h)-diones for use as matrix metalloproteinase (mmp) inhibitors
CN1187332C (zh) * 2002-04-26 2005-02-02 中国科学院上海有机化学研究所 四氢异喹啉羟肟酸磺酰胺类化合物、合成方法及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006410A1 (fr) * 1997-08-04 1999-02-11 Amgen Inc. Inhibiteurs de metalloproteases heterocycliques hybrides et substitues par de l'acide hydroxamique

Also Published As

Publication number Publication date
WO2005073236A2 (fr) 2005-08-11
US7399770B2 (en) 2008-07-15
JP2007519654A (ja) 2007-07-19
WO2005073236A3 (fr) 2006-01-26
US20070093482A1 (en) 2007-04-26
DE102004004974A1 (de) 2005-08-18
JP4733648B2 (ja) 2011-07-27

Similar Documents

Publication Publication Date Title
WO2005073236A2 (fr) Derives de thieno-iminoacide en tant qu'inhibiteurs de metalloproteinases matricielles
EP2069289B1 (fr) DÉRIVÉS D'ISOSÉRINE UTILISÉS COMME INHIBITEURS DU FACTEUR DE COAGULATION IXa
EP2069288B1 (fr) DÉRIVÉS DE TARTRATE UTILISÉS COMME INHIBITEURS DU FACTEUR DE COAGULATION IXa
EP1670766B1 (fr) Derivés d'iminoacides bicycliques pour le traitement (entre autres) d'affections de l'appareil locomoteur
WO2004060883A1 (fr) Diamides de l'acide pyrimidin-4,6-dicarboxylique utilises en tant qu'inhibiteurs selectifs de mmp 13
EP1585728B1 (fr) Derives d'aminoacides utilises en tant qu'inhibiteurs de metalloproteinases matricielles
EP1763515B1 (fr) Acides 4-trifluoromethoxyphenoxybenzene-4'-sulfoniques, leur procede de production et leur utilisation dans des medicaments
DE10251019A1 (de) Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
DE102005002500A1 (de) Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
EP2054412B1 (fr) Dérivé de imino-imidazo-pyridine présentant une activité antithrombotique
WO2003074489A1 (fr) Acides alpha-iminocarboxyliques n-substitues cycliques pour l'inhibition selective de la collagenase
DE10254092A1 (de) Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060831

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LAMPILAS, MAXIME

Inventor name: SCHUDOK, MANFRED

Inventor name: MATTER, HANS

Inventor name: HOFMEISTER, ARMIN

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20101221

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20140127